Faecal Microbiota Transplantation: Looking beyond Clostridium difficile infection at Inflammatory Bowel Disease

Krish Patel, Amee Patel, David Hawes, Janki Shah, Krishna Shah



Gastrointestinal (GI) microbiota are known to play paramount role in inflammatory bowel disease (IBD). Innovative sequencing methods have radically expanded our ability to analyze the intestinal microbiome. However, alterations of the GI microbiome in IBD have not yet been fully evaluated. Irregular colonization of the gut has been implicated in chronic intestinal inflammation. Faecal microbiota transplantation (FMT) is a procedure which aims to restore microbial disturbances to the individual’s gut microbiome. The success of FMT in Clostridium difficile infection (CDI) has inspired studies to explore transplantation in other conditions such as IBD. Ulcerative colitis (UC) and Crohn’s disease (CD), the two principal manifestations of IBD, are emerging as a worldwide epidemic and are multifactorial in aetiology. There have been various case series in the past looking at the use of FMT in IBD, with a large number of them focusing on UC; however, two new randomized controlled trials shed up-to-date light on the complex interactions between the GI microbiome and patients. Regardless of these new studies, much more remains unknown about the efficacy and safety profile of FMT in IBD, ultimately casting a shadow over its use as a therapeutic intervention in conditions other than CDI. Further researches are necessary to fully evaluate the role of FMT as a management option in IBD. In this review, we discuss and summarize the functions of FMT in IBD, and the relationship between IBD and the GI microbial variations present.
Keywords: Inflammatory bowel disease, Ulcerative colitis, Crohn’s disease, Faecal microbiota transplantation.
(Please cite as: Patel K, Patel A, Hawes D, Shah J, Shah K. Faecal microbiota transplantation: looking beyond clostridium difficile infection at inflammatory bowel disease. Gastroenterol Hepatol Bed Bench 2018;11(1):1-8).


Inflammatory bowel disease; Ulcerative colitis; Crohn’s disease; Faecal microbiota transplantation

Full Text:

PDF - View Count=34


Turnbaugh P, Ley R, Hamady M, Fraser-Liggett C, Knight R, Gordon J. The human microbiome project: exploring the microbial part of ourselves in a changing world. Nature. 2007;449 (7164): 804-10. Available at: http://www.nature.com/nature/journal/v449/n7164/full/nature06244.html

Khoruts A, Sadowsky MJ, Hamilton MJ. Development of fecal microbiota transplantation suitable for mainstream medicine. Clin Gastroenterol Hepatol. 2015;13 (2): 246-50. Available at: http://www.sciencedirect.com/science/article/pii/S1542356514016395

Kassam Z, Lee CH, Yuan Y, Hunt RH. Fecal microbiota transplantation for Clostridium difficile infection: systematic review and meta-analysis. Am J Gastroenterol. 2013;108 (4): 500-8. Available at: http://www.nature.com/ajg/journal/v108/n4/full/ajg201359a.html

Young VB. Therapeutic manipulation of the microbiota: past, present, and considerations for the future. Clin Microbiol Infect. 2016;22 (11): 905-9. Available at: http://www.sciencedirect.com/science/article/pii/S1198743X1630386X

Konig J, Siebenhaar A, Högenauer C, Arkkila P, Nieuwdorp M, Norén T et al. Consensus report: faecal microbiota transfer - clinical applications and procedures. Aliment Pharmacol Ther. 2017;45 (2): 222-39. Available at: http://onlinelibrary.wiley.com/doi/10.1111/apt.13868/abstract;jsessionid=C6A8690FD70BCA798C561CAD8B36702F.f03t03

Rossen NG, MacDonald JK, de Vries EM, D'Haens GR, de Vos WM, Zoetendal EG et al. Fecal microbiota transplantation as novel therapy in gastroenterology: A systematic review. World J Gastroenterol. 2015;21 (17): 5359-71. Available at: http://www.wjgnet.com/1007-9327/full/v21/i17/5359.htm

Ye Y, Pang Z, Chen W, Ju S, Zhou C. The epidemiology and risk factors of inflammatory bowel disease. Int J Clin Exp Med. 2015;8 (12): 22529-42. Available at: http://www.ijcem.com/files/ijcem0015728.pdf

Lichtenstein GR, Hanauer SB, Sandborn WJ. Management of Crohn's disease in adults. Am J Gastroenterol. 2009;104 (2): 465-83. Available at: http://www.nature.com/ajg/journal/v104/n2/full/ajg2008168a.html

Qiao YQ, Cai CW, Ran ZH. Therapeutic Modulation of the Gut Microbiota in IBD - More Questions to Be Answered. J Dig Dis. 2016 Oct 15. doi: 10.1111/1751-2980.12422. [Epub ahead of print] Available at: http://onlinelibrary.wiley.com/doi/10.1111/1751-2980.12422/abstract

Asquith M, Powrie F. An innately dangerous balancing act: intestinal homeostasis, inflammation, and colitis-associated cancer. J Exp Med. 2010;207 (8): 1573. Available at: http://jem.rupress.org/content/207/8/1573

Sartor RB. Microbial influences in inflammatory bowel diseases. Gastroenterology. 2008;134 (2): 577-94. Available at: http://www.sciencedirect.com/science/article/pii/S0016508507021579

Casellas F, Borruel N, Papo M, Guarner F, Antolín M, Videla S et al. Antiinflammatory effects of enterically coated amoxicillin-clavulanic acid in active ulcerative colitis. Inflamm Bowel Dis. 1998 Feb;4(1): 1-5.

Manichanh C, Borruel N, Casellas F, Guarner F. The gut microbiota in IBD. Nat Rev Gastroenterol Hepatol. 2012; 9 (10): 599-608. Available at: http://www.nature.com/nrgastro/journal/v9/n10/full/nrgastro.2012.152.html

Llopis M, Antolin M, Carol M, Borruel N, Casellas F, Martinez C et al. Lactobacillus casei downregulates commensals' inflammatory signals in Crohn's disease mucosa. Inflamm Bowel Dis. 2009;15 (2): 275-83.

Pender SL. Do metalloproteinases contribute to tissue destruction or remodeling in the inflamed gut? Inflamm Bowel Dis. 2008;14: p S136-7.

Damman CJ, Miller SI, Surawicz CM, Zisman TL. The microbiome and inflammatory bowel disease: is there a therapeutic role for fecal microbiota transplantation? Am J Gastroenterol. 2012;107 (10): 1452-9. Available at: http://www.nature.com/ajg/journal/v107/n10/full/ajg201293a.html

Tedelind S, Westberg F, Kjerrulf M, Vidal A. Anti-inflammatory properties of the short-chain fatty acids acetate and propionate: a study with relevance to inflammatory bowel disease. World J Gastroenterol. 2007;13 (20): 2826-32. Available at: http://www.wjgnet.com/1007-9327/full/v13/i20/2826.htm

Machiels K, Joossens M, Sabino J, De Preter V, Arijs I, Eeckhaut V et al. A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis. Gut. 2014;63 (8): 1275-83. Available at: http://gut.bmj.com/content/63/8/1275.long

Sokol H, Pigneur B, Watterlot L, Lakhdari O, Bermúdez-Humarán LG, Gratadoux JJ et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci U S A. 2008;105 (43):16731-6. Available at: http://www.pnas.org/content/105/43/16731.long

Sha S, Xu B, Wang X, Zhang Y, Wang H, Kong X et al. The biodiversity and composition of the dominant fecal microbiota in patients with inflammatory bowel disease. Diagn Microbiol Infect Dis. 2013;75 (3):245-51. Available at: http://www.sciencedirect.com/science/article/pii/S0732889312005056

Donohoe DR, Garge N, Zhang X, Sun W, O’Connell TM, Bunger MK et al. The Microbiome and Butyrate Regulate Energy Metabolism and Autophagy in the Mammalian Colon. Cell Metab. 2011;13 (5): 517–526. Available at: http://www.cell.com/cell-metabolism/abstract/S1550-4131(11)00143-4?_returnURL=http%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS1550413111001434%3Fshowall%3Dtrue

Ott SJ, Musfeldt M, Wenderoth DF, Hampe J, Brant O, Fölsch UR et al. Reduction in diversity of the colonic mucosa associated bacterial microflora in patients with active inflammatory bowel disease. Gut. 2004;53 (5): 685–693. Available at: http://gut.bmj.com/content/53/5/685

Frank DN, St Amand AL, Feldman RA, Boedeker EC, Harpaz N, Pace NR. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci U S A. 2007;104 (34): 13780–13785. Available at: http://www.pnas.org/content/104/34/13780

Willing BP, Dicksved J, Halfvarson J, Andersson AF, Lucio M, Zheng Z et al. A pyrosequencing study in twins shows that gastrointestinal microbial profiles vary with inflammatory bowel disease phenotypes. Gastroenterology. 2010;139 (6): 1844-1854. Available at: http://www.sciencedirect.com/science/article/pii/S0016508510012990

Lepage P, Häsler R, Spehlmann ME, Rehman A, Zvirbliene A, Begun A et al. Twin study indicates loss of interaction between microbiota and mucosa of patients with ulcerative colitis. Gastroenterology. 2011;141 (1): 227-36. Available at: http://www.sciencedirect.com/science/article/pii/S0016508511005208

Martinez C, Antolin M, Santos J, Torrejon A, Casellas F, Borruel N et al. Unstable composition of the fecal microbiota in ulcerative colitis during clinical remission. Am J Gastroenterol. 2008;103 (3): 643-8. Available at: http://www.nature.com/ajg/journal/v103/n3/full/ajg200850131a.html

Ott SJ, Musfeldt M, Wenderoth DF, Hampe J, Brant O, Fölsch UR et al. Reduction in diversity of the colonic mucosa associated bacterial microflora in patients with active inflammatory bowel disease. Gut. 2004;53 (5): 685-93. Available at: http://gut.bmj.com/content/53/5/685.long

Manichanh C, Rigottier‐Gois L, Bonnaud E, Gloux K, Pelletier E, Frangeul L et al. Reduced diversity of faecal microbiota in Crohn's disease revealed by a metagenomic approach. Gut. 2006;55 (2): 205–211. Available at: http://gut.bmj.com/content/55/2/205

Scanlan PD, Shanahan F, O’Mahony C, Marchesi JR. Culture-Independent Analyses of Temporal Variation of the Dominant Fecal Microbiota and Targeted Bacterial Subgroups in Crohn's Disease. J Clin Microbiol. 2006;44 (11): 3980–3988. Available at: http://jcm.asm.org/content/44/11/3980

Barcenilla A, Pryde SE, Martin JC, Duncan SH, Stewart CS et al. Phylogenetic relationships of butyrate-producing bacteria from the human gut. Appl Environ Microbiol. 2000;66 (4): 1654–1661. Available at: http://aem.asm.org/content/66/4/1654.long

Chassaing B, Darfeuille-Michaud A. The commensal microbiota and enteropathogens in the pathogenesis of inflammatory bowel diseases. Gastroenterology. 2011;140 (6): 1720-28. Available at: http://www.sciencedirect.com/science/article/pii/S0016508511001612

Chassaing B, Rolhion N, de Vallée A, Salim SY, Prorok-Hamon M, Neut C et al. Crohn disease–associated adherent-invasive E. coli bacteria target mouse and human Peyer’s patches via long polar fimbriae. J Clin Invest. 2011;121 (3): 966–975. Available at: http://www.jci.org/articles/view/44632

Bennet JD, Brinkman M. Treatment of ulcerative colitis by implantation of normal colonic flora. Lancet. 1989;1 (8630): 164.

Borody TJ, George L, Andrews P, Brandl S, Noonan S, Cole P et al. Bowel-flora alteration: a potential cure for inflammatory bowel disease and irritable bowel syndrome? Med J Aust. 1989;150 (10):604.

Suskind DL, Singh N, Nielson H, Wahbeh G. Fecal microbial transplant via nasogastric tube for active pediatric ulcerative colitis. J Pediatr Gastroenterol Nutr. 2015;60 (1): 27-9.

Paramsothy S, Kamm MA, Walsh A, van den Bogaerde J, Samuel D, Leong RW et al. 600 Multi Donor Intense Faecal Microbiota Transplantation is an Effective Treatment for Resistant Ulcerative Colitis: A Randomised Placebo-Controlled Trial. Gastroenterology. 2016;150 (4): S122-123. Available at: http://www.sciencedirect.com/science/article/pii/S0016508516305170

Borody TJ, Warren EF, Leis S, Surace R, Ashman O. Treatment of ulcerative colitis using fecal bacteriotherapy. J Clin Gastroenterol. 2003;37 (1): 42-7.

Vermeire S, Joossens M, Verbeke K, Wang J, Machiels K, Sabino J et al. Donor Species Richness Determines Faecal Microbiota Transplantation Success in Inflammatory Bowel Disease. J Crohns Colitis. 2016;10 (4): 387-94. Available at: https://academic.oup.com/ecco-jcc/article-lookup/doi/10.1093/ecco-jcc/jjv203

Moayyedi P, Surette MG, Kim PT, Libertucci J, Wolfe M, Onischi C et al. Fecal Microbiota Transplantation Induces Remission in Patients With Active Ulcerative Colitis in a Randomized Controlled Trial. Gastroenterology. 2015;149 (1): 102-109. Available at: http://www.sciencedirect.com/science/article/pii/S0016508515004515

Rossen NG, Fuentes S, van der Spek MJ, Tijssen JG, Hartman JH, Duflou A et al. Findings From a Randomized Controlled Trial of Fecal Transplantation for Patients With Ulcerative Colitis. Gastroenterology. 2015;149 (1): 110-118. Available at: http://www.sciencedirect.com/science/article/pii/S0016508515004485

Vermeire S, Joossens M, Verbeke K, Wang J, Machiels K, Sabino J et al. Donor Species Richness Determines Faecal Microbiota Transplantation Success in Inflammatory Bowel Disease. J Crohns Colitis. 2016;10 (4): 387-94. Available at: https://academic.oup.com/ecco-jcc/article-lookup/doi/10.1093/ecco-jcc/jjv203

Cui B, Feng Q, Wang H, Wang M, Peng Z, Li P et al. Fecal microbiota transplantation through mid-gut for refractory Crohn's disease: safety, feasibility, and efficacy trial results. J Gastroenterol Hepatol. 2015;30 (1): 51-8. Available at: http://onlinelibrary.wiley.com/wol1/doi/10.1111/jgh.12727/full

Vaughn BP, Gevers D, Ting A, Korzenik JR, Robson SC, Moss AC. Mo1228 Fecal Microbiota Transplantation Induces Early Improvement in Symptoms in Patients With Active Crohn's Disease. Gastroenterology. 2014;146 (5): S591-592. Available at: http://www.sciencedirect.com/science/article/pii/S0016508514621430

Suskind DL, Brittnacher MJ, Wahbeh G, Shaffer ML, Hayden HS, Qin X et al. Fecal microbial transplant effect on clinical outcomes and fecal microbiome in active Crohn's disease. Inflamm Bowel Dis. 2015;21 (3): 556-63.

Agrawal M, Aroniadis OC, Brandt LJ, Kelly C, Freeman S, Surawicz C et al. The Long-term Efficacy and Safety of Fecal Microbiota Transplant for Recurrent, Severe, and Complicated Clostridium difficile Infection in 146 Elderly Individuals. J Clin Gastroenterol. 2016;50 (5): 403-7.

De Leon LM, Watson JB, Kelly CR. Transient flare of ulcerative colitis after fecal microbiota transplantation for recurrent Clostridium difficile infection. Clin Gastroenterol Hepatol. 2013;11 (8): 1036-8. Available at: http://www.sciencedirect.com/science/article/pii/S1542356513006204

DOI: http://dx.doi.org/10.22037/ghfbb.v0i0.1095

Creative Commons License
GHFBB by Gastroenterology and Liver Diseases Research Institute is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.


PISSN: 2008-2258

EISSN: 2008-4234


Privacy Policy | For Author | Online Submission | About | Contact

Copyright © 2016 Shahid Beheshti University of Medical Sciences. All rights reserved.